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Lipopolysaccharide (LPS), an endotoxin from Gram-negative bacteria, acts as a potent stimulator of microglia and has been
used to study the inflammatory process in the pathogenesis of Parkinson’s disease (PD) and anti-inflammatory therapy for PD
treatment. Here, we review the growing body of literature on both in vitro and in vivo LPS PD models. Primary cell cultures from
mesencephalic tissue were exposed to LPS in vitro; LPS was stereotaxically injected into the substantia nigra, striatum, or globus
pallidus of brain or injected into the peritoneal cavity of the animal in vivo. In conclusion, the LPS PD models are summarized
as (1) local and direct LPS treatment and (2) systemic LPS treatment. Mechanisms underlying the PD models are investigated
and indicated that LPS induces microglial activation to release a variety of neurotoxic factors, and damaged neurons may trigger
reactive microgliosis, which lead to progressive dopaminergic neurodegeneration.
1. Introduction
Parkinson’s disease (PD) is the most prevalent neurode-
generative movement disorder. In PD, clinical symptoms
including tremor, rigidity, and bradykinesia are primarily
resulted from the loss of dopamine-containing neurons in
the substantia nigra pars compacta. Although the etiology
and pathogenesis of PD remain not fully elucidated, many
interacting pathological processes appear to contribute to
dopaminergic neuron degeneration in the disease. Recently,
inflammatory processes have been implicated as one of
the active contributors to dopaminergic neuron damage
in the development and progression of the disease [1,
2]. In the central nervous system, microglia, the resident
innate immune cells, play a major role in the inflammatory
process. Typically microglia exist in a resting state char-
acterized by ramified morphology and monitor the brain
environment [3]. In response to various pathogenic stimuli
including inflammation, microglia are readily activated and
undergo a transformation to amoeboid morphology with an
upregulated catalogue of surface molecules [3–5]. Activated
microglia can serve diverse beneficial functions essential
to neuron survival, which include cellular maintenance
and innate immunity [6]. However, uncontrolled activated
microglia produces a variety of neurotoxic factors such
as proinflammatory cytokines (interleukin-1 (IL-1), tumor
necrosis factor alpha (TNF-α), interleukin-6 (IL-6)), nitro
oxide (NO), prostaglandin E2, and superoxide, which lead
to neuronal damage or death [1, 7–10]. Additionally, dam-
aged neurons may emit injury signals to cause microglia
activation, which used to be defined as reactive microgliosis
[11]. This microglial-neuronal interaction will be reinforced
and become a self-amplifying cycle of neuronal injury and
microglial activation, which finally leads to more neuronal
damage and death. Importantly, clinical researches have
reported that microglial activation was found in the nigros-
triatal system of PD patients [12–14]. Therefore, it is essential
to study the inflammatory process in PD, which may help
us understand the pathogenesis of the disease and eventually
develop an effective therapeutic strategy.
Over the last two decades, studies in animal models have
demonstrated that inflammation induced by lipopolysac-
charide (LPS) can replicate some characteristics of PD,
including extensive activation of microglia and selective loss
of dopaminergic neurons in the nigrostriatal system [15–19].
The history of understanding LPS starts in the late nineteenth
century. LPS is found in the outer membrane of Gram-
negative bacteria and acts as endotoxin. LPS from many
Gram-negative bacteria species initiates acute inflammatory
responses in mammals and induces a diverse range of effects,
ranging from pyrexia to Gram-negative septic shock [20].
Thus, using different serotypes of LPS and their different
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application routes may cause different outcomes [21]. More-
over, LPSs from different bacteria species share common fea-
tures in their basic architecture, which consists of three cova-
lently linked segments, a surface carbohydrate polymer (O-
specific chain), a core oligosaccharide featuring an outer and
inner region, and an acylated glycolipid (termed lipid A). The
O-specific chain shows the most diversity and is the basis for
serological specificity, while lipid A, which anchors the LPS
molecule in the Gram-negative outer membrane, is the most
conserved biochemical structure across different bacterial
species [20]. There is wide acceptance that the lipid A moiety
is the innate immune stimulating or endotoxic component of
LPS [22]. In addition, it is documented that LPS-associated
pathology results from the stimulation of host cell responses,
in which LPS binds to specific receptors in order to elicit the
release of cytokines and other inflammatory mediators. Sev-
eral membrane-bound and soluble proteins have been shown
to bind LPS; themost important appear to be CD14 and LPS-
binding protein (LBP) and the toll-like receptor (TLR) family
which is a recently discovered group of transmembrane
receptors [23, 24]. In the central nervous system, it is
found that systemic LPS injection upregulated its membrane
CD14 receptor within specific cellular populations including
microglia in the brain [25]. Thereafter, microglia were
identified as the major LPS-responsive cell in the brain. LPS
binds to TLR4 onmicroglia and inducesmicroglial activation
that results in neuronal damage [26, 27].
LPS acts as an endotoxin and elicits multiple pathological
effects in human beings. One case report may uncover a
potential link between LPS infection and the development
of Parkinsonism. A 22-year-old laboratory worker was acci-
dentally exposed to 10 μg Salmonella minnesota LPS through
an open wound and developed Parkinson’s syndrome with
bradykinesia, rigidity, tremor, and cogwheel phenomenon
three weeks later; damage to the substantia nigra and
cerebral cortex was shown by positron emission tomography
a few years after the accident [28]. However, it is known
that LPS from many bacterial species such as Salmonella,
Pseudomonas, Vibrio, and Rhizobium can initiate acute
inflammatory responses in mammals and induce a large and
diverse range of effects, ranging from pyrexia and Gram-
negative septic shock [29]. There is another case report
regarding the Salmonella endotoxin exposure. One middle-
aged laboratory worker was self-administered intravenously
a single large dose of endotoxin (1mg Salmonella minnesota
LPS) and immediately developed a severe septic shock
syndrome with multiple-organ dysfunction. The patient
was successfully rescued in the emergency room, and there
has been no follow-up report to date [30]. Thus, further
investigation and more epidemiologic data are needed to
exploit the relationship between endotoxin and PD.
In the current paper, we present a summary of a variety
of LPS PDmodels and discuss their strengths and limitations,
which may be helpful for the future LPS PD study.
2. In Vitro Studies of LPS PD Model
2.1. LPS Treatment to Cell Culture from Mesencephalic Tissue.
Bronstein et al. in 1995 reported the comparison study
between the dopaminergic neurotoxin 6-hydroxydopamine
(6-OHDA) and LPS in rat mesencephalic cultures [31].
Investigators found that, in the neuron-enriched cultures,
6-OHDA killed 89% of the tyrosine hydroxylase- (TH-)
immunopositive neurons, but LPS (50 μg/mL) was not
neurotoxic; however, in the mixed neuron-glial cultures, 6-
OHDA killed only 27% of the TH-immunopositive neurons,
but LPS killed 70% of the TH-immunopositive neurons. This
early experiment suggested that the dopaminergic neuro-
toxicity of LPS is dependent on the presence of microglia.
Subsequently, dopaminergic neurotoxicity of LPS was con-
firmed by the other groups on rat mesencephalic mixed
neuron-glial cultures and demonstrated that LPS induced
microglial activation, and activated microglia released the
proinflammatory and cytotoxic factors: NO, TNF-α, and IL-
1β, which lead to dopaminergic neuron damage [32, 33]. In
addition, the dopaminergic neurotoxicity of LPS was studied
on mouse mesencephalic neuron-glial culture, and it was
found that the neurotoxicity was mainly mediated through
LPS-induced nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase activation on microglia, which generated
reactive oxygen species production, which are neurotoxic
factors [34].
In the studies of LPS-treated primary cultures generated
from forebrains of embryonic day 17 mice, the investigators
found that the LPS neurotoxicity occurred through binding
the signal-transducing receptor, TLR4; microglia are the
major cells in the central nervous system that express
TLR4. However, it is emphasized that the toxic effect of
LPS on neurons is a general phenomenon, independent of
neuronal subtype [26]. Thus, LPS may cause neurotoxicity
without selectivity for neuronal types. Since previous studies
from primary microglia cultures have found LPS treatment
induced the release of proinflammatory and cytotoxic factors
from microglia [35, 36], the investigators suggested that the
activation of TLR4 onmicroglia may initiate the intracellular
signaling pathway of microglia, and result in the release of
proinflammatory mediators which cause neuronal damage
[26].
3. In Vivo Studies of LPS PD Model
3.1. Intranigral Injection of LPS. In order to study the
response of the nigrostriatal system to inflammation, Bing
et al. and Castan˜o et al. independently reported the PD
model of LPS intranigral injection in 1998 [15, 16]. After
LPS was stereotaxically injected into the nigral area of rats,
investigators found that LPS induced microglia activation
and dopaminergic neuron loss in the substantia nigra [15,
16]. In a following study, it was reported that LPS-induced
dopaminergic neuronal damage was permanent, as observed
one year postinjection. Moreover, there was no detectable
damage to either the GABAergic or the serotoninergic
neurons in the striatum and nigra after LPS injection,
indicating that LPS selectively induced dopaminergic neuron
death in the nigrostriatal system [37]. Thereafter, more
studies confirmed the results and also found the increased
level of proinflammatory cytokines including IL-1β, TNF-
α, IL-6, and NO in the substantia nigra after LPS injection,
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which may be causal factor for LPS-induced neuronal
damage [38–40]. In addition, the effects of intranigral LPS
injection on behavior and dopamine content and turnover
were investigated and showed that LPS treatment enhanced
locomotor activity 2- to 3-fold and increased dopamine
turnover ratios in comparison with control subjects. This
suggests that LPS insult may induce a compensatory response
of dopaminergic system [41].
3.2. Intrapallidal Injection of LPS. The globus pallidus is a
major integrative nucleus within the basal ganglia, with neu-
rons projecting to striatum, subthalamic nucleus, entope-
duncular nucleus, and substantia nigra. Thus, the globus
pallidus is positioned to influence the nigrostriatal pathway
and function of the basal ganglia as a whole. LPS was injected
into the globus pallidus of young and middle-aged rats. The
results showed that microglial activation was found in both
globus pallidus and substantia nigra, dopaminergic neurons
were significantly and progressively decreased in the substan-
tia nigra, and locomotor deficits were detected in animal after
LPS injection [17]. Moreover, the following study reported
an increased level of proinflammatory cytokines including
IL-1β, TNF-α, and IL-6, the elevated expression of inducible
nitric oxide synthase, and the enhanced α-synuclein nitration
and oligomerization in the substantia nigra of LPS-injected
animal [42]. Interestingly, the above pathological changes
were much severer in middle-aged animals when compared
with the younger animals after LPS treatment, supporting the
view that aging itself is a risk factor for PD development [42].
Inflammation promotes the release of neurotoxic factors and
the development of synucleinopathy lesions that finally lead
to dopaminergic neurodegeneration in PD model of LPS
intrapallidal injection. Additionally, the finding of abnormal
α-synuclein may help us to explore the mechanisms under-
lying progressive loss of dopaminergic neurons in LPS PD
models. It is reported that aggregated α-synuclein induced
microglial activation in a primary mesencephalic neuron-glia
culture system [43], thus the pathological process of reactive
microgliosis may be triggered and microglial activation may
become uncontrolled, which eventually result in progressive
dopaminergic neurotoxicity.
3.3. Intrastriatal Injection of LPS. In the nigrostriatal system,
the cell bodies of dopaminergic neurons are located in the
substantia nigra and their dopamine-containing terminals
are distributed in the striatum. After LPS was injected into
the striatum of rats, we detected a progressive degeneration
of dopamine cell bodies in the substantia nigra and their
axonal terminals in the striatum, a depletion of dopamine
content in the striatum, cytoplasmic accumulation of α-
synuclein and ubiquitin in the nigral dopamine neu-
rons, and behavioral deficits assessed by cylinder test and
amphetamine-induced rotational behavior behavioral test
[19, 44–46]. Molecular mechanisms underlying the neuro-
toxicity of LPS intrastriatal injection included activation of
microglia, impairment of mitochondria state III and state
V respiration, and an increased release of proinflammatory
mediators: IL-1β, TNF-α, IL-6, IL-1α, and NO, in both
the substantia nigra and the striatum. This indicates that
the inflammatory insult or stimuli in the striatum not only
directly damaged the terminals of dopaminergic neurons in
the striatum, but also indirectly damaged the cell bodies of
dopaminergic neurons in the substantia nigra through an
unknown retrograde signal transduction pathway [19, 44,
45].
3.4. Intraperitoneal/Systemic Injection of LPS. To study how
infectious disease through blood transmission affects the
development of neurodegenerative disease in the central
nervous system, LPS was systemically injected into animals.
Early work reported that after systemic (intraperitoneal or
intravenous) injection of LPS, LPS has the ability to target the
brain in upregulating its membrane CD14 receptor within
specific cellular populations including microglia, which is
likely to be responsible for the transcription of proinflam-
matory cytokines: first within accessible structures from the
blood and thereafter through scattered parenchymal cells
during severe sepsis [25]. In addition, early work also showed
that intraperitoneal endotoxin even at a high dose (2mg/kg
of LPS, which has cardiovascular effects, e.g., a decrease
in blood pressure) into rats did not disrupt blood-brain
barrier (BBB) permeability, suggesting that intraperitoneal
LPS administration is unlikely to contribute to the observed
central nervous system mediated effects of endotoxin [47].
However, other studies have found that some cytokines
including TNF-α and IL-1 can be transported across the
BBB by saturable transport systems, which are able to
directly affect central nervous system functions [48, 49].
Using the intraperitoneal injection of LPS in mice, Qin
et al. reported that increased cytokine TNF-α due to LPS
insult was critical for the transfer of inflammation from the
periphery to the central nervous system to induce microglial
activation and dopaminergic neuron loss in the substantia
nigra at 7 and 9 months posttreatment [18]. Nevertheless,
Byler et al. found that systemic LPS injection alone did
not affect dopamine levels or Parkinsonian behavioral tests
in mice whereas systemic LPS plus MPTP in combination
induced the depletion of dopamine in the striatum and
Parkinsonian behavioral deficits (reduced stride length) at
4 months postinjection [50]. In addition, MPTP treatment
alone reduced striatal dopamine levels quickly but they
recovered to normal levels later, addressing the point that
nigrostriatal dopamine neurons may succumb after time to
multiple toxic agents [50].
4. ImplicationUsing the Animal LPS PDModels
A number of studies have suggested that microglial activation
plays a key role in the initiation and progression of PD
[8, 12, 13, 51, 52]. LPS PD models provide us with
a good tool to investigate the inflammatory process in
PD development and anti-inflammation therapy for PD
treatment. For example, naloxone, an antagonist of opioid
receptors, provided the dopaminergic neuroprotective effects
against LPS damage [32, 38, 53]. Interleukin-10, a natural
immune modulator, reduced LPS-induced dopaminergic
neurotoxicity by inhibiting microglial activation [40, 54].
Pioglitazone, an agonist of peroxisome proliferator-activated
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Figure 1: LPS induces progressive neurotoxicity. In response to LPS stimuli, microglial cells are readily activated. It is demonstrated
that LPS binds to specific receptors, for example, CD14/TLR4/LBP receptor complex on the microglia, to induce microglial activation.
Uncontrolled microglial activation produce a variety of neurotoxic factors such as proinflammatory cytokines (IL-1, TNF-α, IL-6), NO,
PGE2, and O2
−, which lead to neuronal damage or death through a cascade of events such as oxidative/nitrative stress, mitochondrial
dysfunction, and apoptosis. Moreover, damaged neurons may emit injury signals to cause microglia activation, which is defined as reactive
microgliosis. The injury signals could be neuromelanin and α-synuclein released by injured dopaminergic neurons. This microglial-neuronal
interaction will be reinforced and become a self-amplifying cycle of neuronal injury and microglial activation, which may finally result in
the neurodegenerative disease.
receptor gamma, improved dopaminergic neuron survival
by restoring mitochondrial function, decreasing the release
of proinflammatory mediators and suppressing the oxida-
tive stress [33, 45, 55, 56]. Minocycline, a semisynthetic
second-generation tetracycline, exerts potential neuropro-
tective effects by reducing the inflammatory response and
inhibiting apoptotic cell death [57–59]. Among all of these,
minocycline is receiving a great deal of attention for its
potent antiinflammatory and anti-apoptosis effects. It has
been demonstrated that minocycline has few safety concerns
and that it should be considered for a large phase III efficacy
trial after phase II clinical trials in early PD patients [60, 61].
Currently, minocycline is used inmany ongoing clinical trials
for various diseases including PD [62].
5. Discussion of LPS PD Models
Mechanisms underlying the LPS PD models are investi-
gated and indicated that LPS induces microglial activation,
activated microglia release proinflammatory and neurotoxic
factors such as IL-1, TNF-α, IL-6, and NO to cause neuronal
damage [40, 42, 63], and damaged neuron may emit injury
signals such as neuromelanin and abnormal α-synuclein to
trigger reactive microgliosis [43, 64, 65]. This neuronal-
microglial interaction may be reinforced and become a self-
amplifying cycle to result in progressive dopaminergic neu-
rodegeneration (Figure 1). Based on the application routes
in these LPS PD models, we summarize them as follows:
(1) LPS is directly and locally applied into the nigrostriatal
system and its related structures, such as LPS treatment in
mesencephalic cell culture systems in vitro and stereotaxic
injection of LPS in nigra, striatum or globus pallidus in vivo;
(2) LPS is systemically administered and selectively affects
the nigrostriatal system, such as intraperitoneal injection of
LPS in vivo. First, let us discuss the local and direct LPS
treatment of PD models. Many studies have suggested that
dopaminergic neurons are more vulnerable than others in
the nigrostriatal system to inflammation-mediated neuro-
toxicity owing to their precarious redox equilibrium and
colocalization with a large population of microglia [2, 66].
Thus, inflammatory responses induced by direct and local
LPS treatment may selectively cause dopaminergic neuron
damage in mesencephalic tissue in vitro and in the nigrostri-
atal system in vivo. For stereotaxic injection of LPS in nigra,
striatum, or globus pallidus in vivo, because of the smaller
size of the nigral area compared with the striatum/globus
pallidus area and the dense distribution of dopaminergic
neurons in the nigra, intranigral injection itself may cause
severe mechanical injury to neurons and glial cells in the
nigral area whereas intrastriatal/intrapallidal LPS injection
has the advantage of keeping intact the structure of the nigra
for enabling the study of the toxic effect of inflammation on
neurons. Moreover, intrastriatal/intrapallidal LPS treatment
not only induces progressive dopaminergic neuron loss, but
also leads to behavioral deficits in animal studies. Thus
intrastriatal/intrapallidal LPS injection may be a better PD
model in vivo. Next, let us discuss the systemic LPS treatment
of PDmodel. There remains a puzzle how systemic treatment
of LPS selectively induced dopaminergic neuron death in
the nigrostriatal system of brain. We know that LPS acts
as a potent stimulator of microglia and microglia density
varies by brain region in human and animals. It has been
reported that the level of microglial cells was high in the
medulla oblongata and pons in comparison with that in
the substantia nigra, hippocampus, thalamus, basal ganglia,
and pedunculus cerebri in an adult normal human brain
study [67]. Likewise, microglial cells are not uniformly
distributed in the normal adult mouse brain. Lawson et al.
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reported that microglial densely populated areas include the
hippocampus, olfactory telencephalon, basal ganglia, and
substantia nigra in the adult mouse brain [68]. Importantly,
these studies demonstrate that the density of microglial
cells in the substantia nigra is similar to that in the
hippocampus, basal ganglia, and so on for both the human
and mouse brains. In other words, microglia activation
and subsequent proinflammatory cytokines release due to
LPS insult may occur in several brain regions, but not in
nigral area alone. For example, LPS is also widely used in
experimental in vitro and in vivo models of inflammation
and amyloidosis for Alzheimer’s disease [69, 70]. Thus, it
needs further investigation for the selective dopaminergic
neurodegeneration in the substantia nigra after systemic
LPS treatment. In summary, bacterial endotoxin LPS used
as a potent stimulator of glial cells, especially microglia,
help us to study the molecular mechanism underlying
inflammatory processes in neurodegenerative diseases in the
central nervous system. Direct and local LPS treatment in the
nigrostriatal system and its related structures may be better
PD models to study the etiology and therapeutic strategies
for inflammation in PD.
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